|
Lymphoma, Follicular
|
0.100 |
Biomarker
|
disease |
BEFREE |
A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response.
|
10848785 |
2000 |
|
Lymphoma, Follicular
|
0.100 |
Biomarker
|
disease |
BEFREE |
AME-133v showed encouraging results as an anti-CD20 therapy in heavily pretreated FL patients with the less favorable FcγRIIIa F-carrier genotype.
|
22223529 |
2012 |
|
Lymphoma, Follicular
|
0.100 |
Biomarker
|
disease |
BEFREE |
GALLIUM is an open-label, parallel-group randomised, phase 3 trial, which recruited previously untreated patients with CD20-positive follicular lymphoma (grades 1-3a; disease stage III/IV, or stage II with largest tumour diameter ≥7 cm) who were aged 18 years or older and met the criteria for needing treatment.
|
30309758 |
2018 |
|
Lymphoma, Follicular
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, other areas had the morphologic and immunohistochemistry pattern of follicular lymphoma (CD20+, CD10+, Bcl2+).
|
18755498 |
2009 |
|
Lymphoma, Follicular
|
0.100 |
Biomarker
|
disease |
BEFREE |
Impressive progress has been made in recent decades for advanced-stage follicular lymphoma with the availability of anti-CD20 monoclonal antibodies, initially rituximab and more recently obinutuzumab.
|
28435325 |
2017 |
|
Lymphoma, Follicular
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In a 3D co-culture assay (MALC), γδ T cells mediate both direct and indirect (ADCC in the presence of anti-CD20 mAbs) cytolytic activity against FL cell aggregates.
|
30723586 |
2019 |
|
Lymphoma, Follicular
|
0.100 |
Biomarker
|
disease |
BEFREE |
In randomised clinical trials, the type II anti-CD20 antibody obinutuzumab has been shown to be more effective than rituximab for therapy of chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL).
|
30042825 |
2018 |
|
Lymphoma, Follicular
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In this study, we used flow cytometry to analyze the expression of CD20, a well-known B-cell-associated antigen, in lymphocytes from 42 cases of CLL and its tissue counterpart, small lymphocytic lymphoma (SLL), and compared the results with results obtained from the analysis of 21 follicular lymphomas, 20 hyperplastic reactive nodes, and 26 samples of normal peripheral blood.
|
1380203 |
1992 |
|
Lymphoma, Follicular
|
0.100 |
Biomarker
|
disease |
BEFREE |
Monotherapy with the anti-CD20 monoclonal antibody rituximab can induce complete responses (CR) in patients with follicular lymphoma (FL).
|
31572357 |
2019 |
|
Lymphoma, Follicular
|
0.100 |
Biomarker
|
disease |
BEFREE |
Most previously untreated patients with CD20+ DLBCL or FL preferred s.c. to i.v. rituximab administration.
|
28031173 |
2017 |
|
Lymphoma, Follicular
|
0.100 |
Biomarker
|
disease |
BEFREE |
Obinutuzumab (G) is a humanized type II, Fc-glycoengineered anti-CD20 monoclonal antibody used in various indications, including patients with previously untreated front-line follicular lymphoma.
|
30866056 |
2019 |
|
Lymphoma, Follicular
|
0.100 |
Biomarker
|
disease |
BEFREE |
Obinutuzumab (OBZ) is a recombinant type II anti-CD20 and immunoglobulin G1 Fc-optimized monoclonal antibody (mAb), recently approved in chronic lymphocytic leukemia (CLL; B-cell CLL) and follicular lymphoma (FL).
|
28584136 |
2017 |
|
Lymphoma, Follicular
|
0.100 |
Biomarker
|
disease |
BEFREE |
Obinutuzumab is a novel glycoengineered, type-II anti-CD20 monoclonal antibody that was recently developed to treat follicular lymphoma (FL), the most prevalent subtype of indolent B-cell lymphoma.
|
31848991 |
2020 |
|
Lymphoma, Follicular
|
0.100 |
Biomarker
|
disease |
BEFREE |
Of those 19, 5 (26.3%; diffuse large B-cell lymphoma [DLBCL], 3 cases; DLBCL transformed from follicular lymphoma, 2 cases) indicated CD20 protein-negative transformation.
|
19246561 |
2009 |
|
Lymphoma, Follicular
|
0.100 |
Biomarker
|
disease |
BEFREE |
Other curcumin-regulated genes identified herein, e.g., CD20, are also seemingly pertinent to the pathophysiology of follicular lymphoma.
|
17198877 |
2007 |
|
Lymphoma, Follicular
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients aged >18 years with CD20+ relapsed/refractory chronic lymphocytic leukaemia (CLL), diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) were enrolled from four centres in China.
|
28072473 |
2017 |
|
Lymphoma, Follicular
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients with previously untreated or relapsed/refractory CD20+ follicular lymphoma received 4 weekly infusions of rituximab and those with a complete response (CR), partial response (PR), or stable disease received mitumprotimut-T and GM-CSF injections subcutaneously.
|
20145546 |
2010 |
|
Lymphoma, Follicular
|
0.100 |
Biomarker
|
disease |
BEFREE |
Phase 1/2 study of ocaratuzumab, an Fc-engineered humanized anti-CD20 monoclonal antibody, in low-affinity FcγRIIIa patients with previously treated follicular lymphoma.
|
24717109 |
2015 |
|
Lymphoma, Follicular
|
0.100 |
Biomarker
|
disease |
BEFREE |
Rituximab is a chimeric anti-CD20 monoclonal antibody that has approval for single agent therapy in the treatment of relapsed/refractory low grade or follicular non-Hodgkin's Lymphoma.
|
11378562 |
2001 |
|
Lymphoma, Follicular
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Sections of axillary lymph node demonstrated potentially 2 clonal processes, PTCL with aberrant CD20 expression and follicular lymphoma.
|
29217426 |
2018 |
|
Lymphoma, Follicular
|
0.100 |
Biomarker
|
disease |
BEFREE |
The cells displayed high avidity and mediated potent cytotoxic effects on cells from patients with the CD20(pos) B cell malignancies follicular lymphoma (FL) and acute lymphoblastic leukemia (ALL).
|
21630262 |
2012 |
|
Lymphoma, Follicular
|
0.100 |
Biomarker
|
disease |
BEFREE |
The clinical application of rituximab (chimeric mouse anti-human CD20 mAb, Rituxan, IDEC-C2B8), alone and/or combined with chemotherapy, has significantly ameliorated the treatment outcome of patients with relapsed and refractory low-grade or follicular non-Hodgkin's lymphoma (NHL).
|
15789036 |
2005 |
|
Lymphoma, Follicular
|
0.100 |
Biomarker
|
disease |
BEFREE |
The combined analysis of CD20 and bcl-2 should be useful for the differential diagnosis between FH and FL and particularly applicable to limited samples or when B-cell clonality is in question.
|
10941341 |
2000 |
|
Lymphoma, Follicular
|
0.100 |
Biomarker
|
disease |
BEFREE |
The first line treatment for symptomatic FL is chemo-immunotherapy followed by two years maintenance therapy with anti-CD20 monoclonal antibodies.
|
29972084 |
2018 |
|
Lymphoma, Follicular
|
0.100 |
Biomarker
|
disease |
BEFREE |
The goal of this trial is a further reduction of the radiation dose in patients with nodal early-stage FL showing a good response to a combination of LDRT and anti-CD20 immunotherapy and a comparison with the currently published MIR trial.
|
31470902 |
2019 |